Clinical Trial Update: A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with XELOX/XELIRI as first-line therapy for unresectable advanced colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• XELIRI
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Jiangsu Cancer Institute & Hospital | Conditions: Advanced Colorectal Cancer | Phase 2 | Status: UNKNOWN